Method for delivering a therapeutic agent into the wall of the small intestine
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/28
A61K-038/26
A61M-031/00
A61K-031/155
A61M-005/20
A61K-038/27
A61K-009/48
A61M-005/168
A61K-038/22
A61K-045/06
A61K-038/29
A61K-009/00
A61K-038/17
A61M-005/172
A61M-005/14
A61M-005/142
출원번호
US-0282864
(2014-05-20)
등록번호
US-9757548
(2017-09-12)
발명자
/ 주소
Imran, Mir A.
출원인 / 주소
Rani Therapeutics, LLC
대리인 / 주소
Wilson Sonsini Goodrich & Rosati
인용정보
피인용 횟수 :
10인용 특허 :
65
초록▼
Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for
Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade within the wall to release the drug to produce a therapeutic effect. The preparation can be coupled to an actuator having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
대표청구항▼
1. A method for delivering a therapeutic agent into the wall of the small intestine, the method comprising: swallowing a drug delivery device comprising a capsule, an actuator having a first configuration and a second configuration and a therapeutic preparation operably coupled to the actuator, the
1. A method for delivering a therapeutic agent into the wall of the small intestine, the method comprising: swallowing a drug delivery device comprising a capsule, an actuator having a first configuration and a second configuration and a therapeutic preparation operably coupled to the actuator, the therapeutic preparation comprising a therapeutically effective dose of at least one therapeutic agent, the preparation being contained within the capsule in the first configuration and advanced out of the capsule and into the small intestine wall in the second configuration so as to deliver the therapeutic agent into the lumen wall, the preparation supplied in the capsule in a shaped form which can be directly delivered from inside the capsule into the wall of the small intestine by the application of force on a surface of the preparation; and actuating the actuator responsive to a condition in the small intestine to directly deliver the therapeutic agent from the capsule into the wall of the small intestine. 2. The method of claim 1, wherein the condition is a selected pH. 3. The method of claim 2, wherein the pH is above about 7.1. 4. The method of claim 1, wherein the therapeutic agent comprises a therapeutically effective dose of insulin for the treatment of diabetes or a glucose regulation disorder. 5. The method of claim 4, further comprising: using the dose of delivered insulin to control a blood glucose level of a patient without injecting insulin into the patient. 6. The method of claim 1, wherein the therapeutic agent comprises a therapeutically effective dose of an incretin for the treatment of diabetes or a glucose regulation disorder. 7. The method of claim 6, further comprising: using the dose of delivered incretin to control a blood glucose level of a patient without injecting incretin into the patient. 8. The method of claim 6, wherein the incretin comprises a glucagon like peptide-1 (GLP-1), a GLP-1 analogue, exenatide, liraglutide, albiglutide, taspoglutide or a gastric inhibitory polypeptide (GIP). 9. The method of claim 6, wherein the incretin comprises exanatide and the dose is in a range from about 1 to 10 μg. 10. The method of claim 1, wherein the therapeutic agent comprises a combination of therapeutic agents for the treatment of diabetes or a glucose regulation disorder. 11. The method of claim 10, further comprising: using the dose of delivered therapeutic agents to control a blood glucose level of a patient without injecting incretin into the patient. 12. The method of claim 11, wherein the combination comprises exenatide and metformin. 13. The method of claim 12, wherein the dosages of the exenatide and the metformin are matched to produce an improved level of blood glucose control for an extended period. 14. The method of claim 13, wherein the extended period is up to about a day. 15. The method of claim 13, wherein the extended period is up to about a week. 16. The method of claim 12, wherein the dose of exenatide is in a range of about 1 to 10 μg and the dose of metformin is in a range of about 1 to 3 grams. 17. The method of claim 10, wherein the combination comprises a therapeutically effective dose of an incretin and a therapeutically effective dose of a biguanide. 18. The method of claim 1, wherein the therapeutic agent comprises a therapeutically effective dose of growth hormone. 19. The method of claim 1, wherein the therapeutic agent comprises a therapeutically effective dose of parathyroid hormone for the treatment of osteoporosis or a thyroid disorder. 20. The method of claim 19, further comprising: using the dose of delivered parathyroid hormone to treat the osteoporosis or a thyroid disorder without injecting parathyroid hormone into the patient. 21. The method of claim 1, wherein the therapeutic agent comprises a therapeutically effective dose of a chemotherapeutic agent for the treatment of cancer. 22. The method of claim 1, wherein the therapeutic agent comprises a therapeutically effective dose of an antibiotic. 23. The method of claim 1, wherein the therapeutic agent comprises a therapeutically effective dose of an antiviral compound. 24. The method of claim 1, further comprising: delivering a first and a second therapeutic agent.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (65)
Kink, John A.; Worledge, Katherine L.; Stafford, Douglas C., Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease.
Wright Jeremy C. (Los Altos CA) Eckenhoff James B. (Los Altos CA) Maruyama Frederick H. (San Jose CA) Peery John R. (Stanford CA), Delivery system comprising means for controlling internal pressure.
Lewkowicz,Shlomo; Gat,Daniel; Kraizer,Yehudit; Gilad,Zvika; Leuw,David; Meron,Gavriel; Glukhovsky,Arkady, Device and method for examining a body lumen.
Hugemann Berhhard (Frankfurt am Main DEX) Schuster Otto (Bad Soden DEX), Device for the release of substances at defined locations in the alimentary tract.
Pasricha Pankaj J. (Columbia MD) Kalloo Anthony N. (Glenndale MD), Device for treating gastrointestinal muscle disorders and other smooth muscle dysfunction.
Imran, Mir; Herrmann, Peter; Syed, Baber; Williams, Timothy H.; Ong, Chang Jin; Method, Greg, Device, system and methods for the oral delivery of therapeutic compounds.
Prausnitz, Mark R.; Allen, Mark G.; Henry, Sebastien; McAllister, Devin V.; Ackley, Donald E.; Jackson, Thomas, Devices and methods for enhanced microneedle penetration of biological barriers.
Yokoi,Takeshi; Takizawa,Hironobu; Segawa,Hidetake; Adachi,Hideyuki, Encapsulated medical device and method of examining, curing, and treating internal region of body cavity using encapsulated medical device.
Lehmann Grard (Neuville de Poitou FRX) Metais Jol (Monts Sur Guesnes FRX) Meunier Jean-Francois (Noisy le Grand FRX) Gautier Jean-Philippe (Ozoir la Ferriere FRX), Implantable drug-dispensing capsule and system facilitating its use.
Truex Buehl E. (Glendora CA) Gibson Scott R. (Granada Hills CA) Weinberg Alvin H. (Moorpark CA), Implantable medical device having shielded and filtered feedthrough assembly and methods for making such assembly.
Brister, Mark C.; Quintana, Nelson; Patel, Kaushik A.; Drake, Neil R.; Llevares, Antonio C.; Markovic, Dubravka; Rasdal, Andrew P.; VandenBerg, Amy D. L., Intragastric device.
Saffran Murray (Toledo OH) Neckers Douglas C. (Perrysburg OH), Method of use of polymers containing cross-linked azo bonds for releasing therapeutic agents into the lower gastrointest.
Nicolaides Ernest D. (Ann Arbor MI) Tinney Francis J. (Ann Arbor MI) Kaltenbronn James S. (Ann Arbor MI) DeJohn Dana E. (Ann Arbor MI) Lunney Elizabeth A. (Ann Arbor MI) Roark W. Howard (Ann Arbor MI, Modified tripeptides.
Eckenhoff ; deceased James B. ; Holladay Leslie A. ; Leonard ; Jr. John Joseph ; Leung Iris K. M. ; Tao Sally A. ; Magruder Judy A. ; Carr John P. ; Wright Jeremy, Peptide/protein suspending formulations.
Imran, Mir, Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device.
Imran, Mir, Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device.
Imran, Mir, Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device.
Imran, Mir, Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device.
Imran, Mir, Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device.
Imran, Mir, Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.